Welcome to our dedicated page for EyePoint Pharmaceuticals news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint Pharmaceuticals stock.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts. The company is committed to developing and commercializing ophthalmic products aimed at treating serious retinal diseases. EyePoint leverages its proprietary Durasert® technology, a sustained intraocular drug delivery system, to create treatments that can provide continuous therapeutic effects for extended periods.
EyePoint Pharmaceuticals has made significant strides in the field of retinal disease treatments. Its lead product candidate, DURAVYU™ (previously known as EYP-1901), is an investigational treatment for VEGF-mediated retinal diseases. This product combines vorolanib, a selective tyrosine kinase inhibitor, with the Durasert® technology to offer sustained delivery and improved patient outcomes. DURAVYU™ is currently undergoing clinical trials for conditions such as wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR).
The company also has several other promising candidates in its pipeline, including EYP-2301, a TIE-2 agonist, and razuprotafib, formulated with Durasert® technology to potentially enhance treatment outcomes for serious retinal diseases.
EyePoint’s innovative approach extends beyond product development to strategic partnerships and collaborations. The company has secured exclusive licenses for vorolanib from Equinox Sciences for all ophthalmic uses outside of China, Macao, Hong Kong, and Taiwan. Additionally, EyePoint has FDA-approved products such as RETISERT® and YUTIQ® that are based on its proprietary drug delivery technology.
Financially, EyePoint Pharmaceuticals has shown a solid performance with total net revenue of $46.0 million for the year ended December 31, 2023, compared to $41.4 million for the previous year. This growth is driven primarily by revenues from royalties and collaborations. The company has also strengthened its financial position with $331.1 million in cash, cash equivalents, and marketable securities as of December 31, 2023.
EyePoint is dedicated to driving innovation in ophthalmology and improving the quality of life for patients with serious eye conditions. With a focus on advancing its robust pipeline through clinical development, EyePoint Pharmaceuticals continues to make headway in addressing unmet medical needs in retinal diseases.
EyePoint Pharmaceuticals, a leader in therapeutics for serious eye disorders, has appointed Michael C. Pine as Chief Corporate Development and Strategy Officer. Pine brings over 20 years of experience in the pharmaceutical sector, previously holding senior roles at Medexus, Lupin, Aralez, and Novartis. His expertise is expected to enhance EyePoint's corporate growth and strategic initiatives, particularly in advancing their product pipeline. In relation to Pine's appointment, 100,000 stock options were granted as part of his inducement award, adhering to Nasdaq guidelines.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced an expanded partnership with ImprimisRx for the U.S. sales and marketing of DEXYCU®, effective January 1, 2022. ImprimisRx will absorb most of EyePoint’s DEXYCU commercial organization, enhancing its ability to promote the injectable steroid treatment for post-operative inflammation. EyePoint retains revenue recognition, manufacturing, and distribution responsibilities. The partnership aims to accelerate DEXYCU’s growth and improve treatment accessibility for patients in need.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the closing of a public offering of 5,122,273 shares of common stock, including 1,095,000 shares purchased under the underwriter's option. The shares were priced at $13.75 each, with pre-funded warrants sold for $13.74 each, generating gross proceeds of approximately $115.4 million. The proceeds will support the Phase 2 clinical trials of EYP-1901 for wet AMD, DR, and RVO, along with earlier-stage pipeline initiatives. The offering was made under an SEC shelf registration statement.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced an underwritten public offering of 4,027,273 shares at $13.75 each, alongside pre-funded warrants for 3,272,727 shares at $13.74 each, aiming for gross proceeds of approximately $100.3 million. The funds will primarily advance EYP-1901 into Phase 2 trials for wet AMD, DR, and RVO, and support pipeline initiatives. The offering is expected to close by November 19, 2021, pending customary conditions.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced an underwritten public offering of $100 million in common stock, with an option for underwriters to purchase an additional $15 million. The offering aims to fund Phase 2 clinical trials for EYP-1901, targeting wet AMD, diabetic retinopathy, and retinal vein occlusion. The proceeds will also support earlier stage pipeline initiatives and general corporate purposes. The securities are offered under a previously filed registration statement, and the offering's completion is subject to market conditions.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced promising six-month interim data from its Phase 1 DAVIO clinical trial of EYP-1901, an investigational treatment for wet age-related macular degeneration (wet AMD). The trial demonstrated a favorable safety profile with no ocular serious adverse events and a 79% reduction in treatment burden. Notably, 76% and 53% of patients did not require rescue treatments up to four and six months, respectively. EyePoint plans to initiate a Phase 2 trial in 2022 and has a Type C meeting with the FDA scheduled for December 1, 2021, to discuss registration trials.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced encouraging six-month interim data from its Phase 1 DAVIO clinical trial of EYP-1901, an anti-VEGF treatment for wet age-related macular degeneration (AMD). Presented at the AAO 2021 Meeting, the trial involved 17 patients, showcasing a 79% reduction in treatment burden and no serious adverse events reported. Patients experienced sustained visual acuity with 76% and 53% not needing rescue therapy after four and six months, respectively. EyePoint plans to advance EYP-1901 into Phase 2 trials in 2022 and engage with the FDA regarding registration trials.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) will have CEO Nancy Lurker present at two virtual conferences: the Jefferies London Healthcare Conference on November 18, 2021, at 3:00 a.m. ET and the 33rd Annual Piper Sandler Virtual Healthcare Conference on November 22, 2021, at 10:00 a.m. ET. The company focuses on developing therapeutics for serious eye disorders, including its Durasert® technology. Webcasts of the presentations will be available on their website, with replays accessible for 30 and 90 days, respectively.
EyePoint Pharmaceuticals (NASDAQ: EYPT) will host a conference call on November 13 at 12:00 P.M. ET to discuss interim data from its Phase 1 DAVIO trial of EYP-1901, aimed at treating wet AMD. The interim results will be presented by Dr. David Boyer during the AAO Retina Subspecialty Day. EYP-1901 is designed for sustained drug delivery through the company's proprietary Durasert technology, which may provide a twice-yearly treatment option for patients. The event will be accessible via phone and webcast on the company's website.
EyePoint Pharmaceuticals (NASDAQ: EYPT) reported its Q3 2021 financial results, highlighting a 49% increase in net product revenue, totaling $8.6 million compared to $5.8 million in the same quarter last year. The Company presented positive safety data from the Phase 1 DAVIO trial for EYP-1901 targeting wet AMD at the ASRS 2021 Annual Meeting. Operating expenses rose to $24.4 million, leading to a net loss of $16.7 million or ($0.58) per share. However, cash reserves improved to $119.7 million, supporting operations through 2022.
FAQ
What is the current stock price of EyePoint Pharmaceuticals (EYPT)?
What is the market cap of EyePoint Pharmaceuticals (EYPT)?
What does EyePoint Pharmaceuticals, Inc. (EYPT) specialize in?
What is DURAVYU™?
Where is EyePoint Pharmaceuticals headquartered?
What are the key products in EyePoint's pipeline?
How did EyePoint Pharmaceuticals perform financially in 2023?
What is the Durasert® technology?
Has EyePoint Pharmaceuticals received FDA approval for any products?
What are the geographical operational footprints of EyePoint Pharmaceuticals?
What is EyePoint's strategy for future growth?
How does EyePoint Pharmaceuticals generate revenue?
